Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that the US Food and Drug Administration (FDA) has approved its Yartemlea ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant- associated thrombotic ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval ...

Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Thinking outside the canon, and finding the gritty and the beautiful, within it. By Joshua Barone and Corinna da Fonseca-Wollheim JOSHUA BARONE Few art forms are as burdened by canons as classical ...

Performances in N.Y.C. Advertisement Supported by A holiday album that cuts through seasonal glut, a late collaboration by Jim McNeely and Helmut Lachenmann’s string quartets are among the highlights.